{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:05:24Z","timestamp":1780477524834,"version":"3.54.1"},"reference-count":25,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Post-remission cytarabine consolidation is a cornerstone of therapy for acute myeloid leukemia (AML), but the optimal dosing strategy in older adults (\u226560 years) remains unclear. High-dose cytarabine (HiDAC) is often avoided due to toxicity concerns, and data guiding cumulative dosing are limited. Methods: We conducted a single-center retrospective cohort study of 111 patients aged \u226560 years with AML who achieved complete remission after standard 7 + 3 induction and received at least one cycle of cytarabine consolidation between 2012 and 2024. A 90-day landmark analysis excluded early relapses or deaths. Results: The median age was 65 years; 41% proceeded to allogeneic hematopoietic stem cell transplantation (allo-SCT). Cytarabine consolidation was well tolerated, with no neurotoxicity and only one instance of reversible nephrotoxicity. Patients were stratified by median cumulative cytarabine dose into low-intensity (&lt;18 g\/m2, LIC) and high-intensity (\u226518 g\/m2, HIC) groups. HIC was associated with improved overall survival compared with LIC (median OS: 31 vs. 13 months, p = 0.02), particularly among non-transplanted patients (25 vs. 7 months, p = 0.01). On multivariable analysis, HIC (HR 0.71, 95% CI 0.51\u20130.82, p = 0.01) and allo-SCT (HR 0.58, 95% CI 0.44\u20130.79, p = 0.03) independently predicted superior survival. Conclusions: Higher cumulative cytarabine consolidation is safe, feasible, and associated with improved survival in older AML patients, especially among patients ineligible for transplant. Prospective studies are warranted to define the optimal dosing strategy in this population.<\/jats:p>","DOI":"10.3390\/cancers18111831","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:58:38Z","timestamp":1780473518000},"page":"1831","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Higher Cumulative Cytarabine Consolidation Improves Survival in Older Adults with Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2300-4499","authenticated-orcid":false,"given":"Todd William","family":"Mudd","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6129-3470","authenticated-orcid":false,"given":"Kendall","family":"Diebold","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-0661","authenticated-orcid":false,"given":"Sravanti","family":"Rangaraju","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimo","family":"Bachiashvili","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel R.","family":"Espinoza-Gutarra","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8233","authenticated-orcid":false,"given":"Razan","family":"Mohty","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-1071","authenticated-orcid":false,"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia","volume":"331","author":"Mayer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood.V80.12.2977.2977","article-title":"Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia","volume":"80","author":"Schiller","year":"1992","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2004-08-2977","article-title":"Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222","volume":"105","author":"Moore","year":"2005","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1200\/JCO.2012.46.4743","article-title":"High-Dose Cytarabine Consolidation With or Without Additional Amsacrine and Mitoxantrone in Acute Myeloid Leukemia: Results of the Prospective Randomized AML2003 Trial","volume":"31","author":"Schaich","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/CIA.S343598","article-title":"Standard-Intensity Induction and Intermediate\/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study","volume":"17","author":"Wang","year":"2022","journal-title":"Clin. Interv. Aging"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2012.47.4874","article-title":"Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial","volume":"31","author":"Burnett","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clml.2015.07.646","article-title":"How Center Volumes Affect Early Outcomes in Acute Myeloid Leukemia","volume":"15","author":"Hahn","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00277-015-2389-9","article-title":"Comparison of consolidation strategies in acute myeloid leukemia: High-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines","volume":"94","author":"Kim","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"Pabst","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2017-04-777722","article-title":"Cytarabine dose in the consolidation treatment of AML: A systematic review and meta-analysis","volume":"130","author":"Magina","year":"2017","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","article-title":"Cytarabine Dose of 36 g\/m2 Compared With 12 g\/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study","volume":"29","author":"Schaich","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.leukres.2013.01.001","article-title":"High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission","volume":"37","author":"Hassanein","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41408-025-01368-9","article-title":"Outcomes of older patients with TP53-mutated myeloid neoplasms","volume":"15","author":"Jamy","year":"2025","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1080\/10428194.2023.2251071","article-title":"Consecutive day dosing of high-dose cytarabine consolidation over 3 days is resource-efficient and safe in older adult patients with acute myeloid leukemia","volume":"64","author":"Nedumannil","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e18535","DOI":"10.1200\/JCO.2025.43.16_suppl.e18535","article-title":"Real-world outcomes of cytarabine consolidation in older patients with acute myeloid leukemia","volume":"43","author":"Dulak","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_17","first-page":"EVIDoa2400326","article-title":"Intermediate-Dose Cytarabine as Postinduction AML Therapy","volume":"4","author":"Hunault","year":"2025","journal-title":"NEJM \u00c9vid."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/bjh.17462","article-title":"High risk of relapse with intermediate dose cytarabine for consolidation in young favourable-risk acute myeloid leukaemia patients following induction with 7 + 3: A retrospective multicentre analysis and critical review of the literature","volume":"194","author":"Kolla","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102187","DOI":"10.1016\/j.jgo.2025.102187","article-title":"Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3","volume":"16","author":"Loh","year":"2025","journal-title":"J. Geriatr. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101555","DOI":"10.1016\/j.jgo.2023.101555","article-title":"Goals, preferences, and concerns of patients with acute myeloid leukemia at time of treatment decision","volume":"14","author":"Jamy","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107393","DOI":"10.1016\/j.leukres.2023.107393","article-title":"Integrating electronic geriatric assessment and frailty screening for adults with acute myeloid leukemia to drive personalized treatment decisions","volume":"134","author":"Jamy","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Qadir, M.S., and Jamy, O. (2026). Landscape of Measurable Residual Disease in Acute Myeloid Leukemia: From Molecular Detection to Clinical Practice. Med. Sci., 14.","DOI":"10.3390\/medsci14010123"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"107920","DOI":"10.1016\/j.leukres.2025.107920","article-title":"Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia","volume":"156","author":"Mudd","year":"2025","journal-title":"Leuk. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e70049","DOI":"10.1002\/jha2.70049","article-title":"Outcomes With Venetoclax 50 mg, Hypomethylating Agents, and Voriconazole or Posaconazole in Acute Myeloid Leukemia","volume":"6","author":"Diebold","year":"2025","journal-title":"eJHaem"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.18229","article-title":"Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia","volume":"198","author":"Jamy","year":"2022","journal-title":"Br. J. Haematol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1831\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:13:35Z","timestamp":1780474415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111831"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111831","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}